Sanofi is to pay Ablynx up to €2.4 billion to develop drugs for immune-related inflammatory diseases based on the biotech’s nanobody technology. The Paris-headquartered pharma firm is ...

During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for Inflammation Research, Ghent University, and University Hospital Ghent, ...

Evox is led by Tony de Fougerolles, a pharma veteran who was previously chief scientific officer of Ablynx, and before that Moderna. De Fougerolles is credited with shifting Moderna’s ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.